Overview

Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma

Status:
Completed
Trial end date:
2019-12-17
Target enrollment:
Participant gender:
Summary
Donafenib versus sorafenib for advanced hepatocellular cancer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Collaborator:
Tigermed Consulting Co., Ltd
Treatments:
Niacinamide
Sorafenib